Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Asset Utilization Ratio (2020 - 2026)

C4 Therapeutics has reported Asset Utilization Ratio over the past 7 years, most recently at 0.1 for Q1 2026.

  • For Q1 2026, Asset Utilization Ratio fell 14.77% year-over-year to 0.1; the TTM value through Mar 2026 reached 0.1, down 14.77%, while the annual FY2025 figure was 0.1, 3.5% up from the prior year.
  • Asset Utilization Ratio for Q1 2026 was 0.1 at C4 Therapeutics, down from 0.12 in the prior quarter.
  • Over five years, Asset Utilization Ratio peaked at 0.12 in Q1 2025 and troughed at 0.04 in Q2 2023.
  • A 5-year average of 0.09 and a median of 0.09 in 2022 define the central range for Asset Utilization Ratio.
  • Biggest five-year swings in Asset Utilization Ratio: plummeted 58.14% in 2023 and later soared 129.92% in 2025.
  • Year by year, Asset Utilization Ratio stood at 0.07 in 2022, then decreased by 16.05% to 0.06 in 2023, then surged by 67.61% to 0.1 in 2024, then increased by 17.37% to 0.12 in 2025, then decreased by 11.95% to 0.1 in 2026.
  • Business Quant data shows Asset Utilization Ratio for CCCC at 0.1 in Q1 2026, 0.12 in Q4 2025, and 0.11 in Q3 2025.